Cortechs.ai | IQ-AI Ltd and Cortechs.ai announce partnership

IQ-AI Ltd and Cortechs.ai announce partnership

Business development agreement provides expanded reach of specialized software to address critical tumor response challenges.  

(SAN DIEGO) — Cortechs.ai and Imaging Biometrics®, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), join forces to increase global access to clinical diagnostic accuracy tools. The non-exclusive business development agreement expands IB’s assortment of quantitative, automated products to Cortechs.ai’ global customer base via its internal sales and marketing teams.

IB’s exclusive algorithms advance clinical understanding of brain tumor pathology by quantitatively distinguishing tumor progression from equivocal MR or CT image artifacts. IB Neuro™ provides a significant leap in magnetic resonance (MR) perfusion analysis and is the only tool of its kind to automatically generate quantitative relative cerebral blood volume (rCBV) maps independent of scanner, field strength, patient or time point. IB Delta Suite™ automates quantitative difference (Delta T1) maps using pre- and post-contrast T1 weighted MRI to help clinicians distinctly establish tumor progression and treatment effect.

Cortechs.ai will additionally distribute IB StoneChecker™, which is in the final stages of FDA clearance. StoneChecker is a semi-automated kidney stone assessment tool that provides physicians with useful clinical metrics instantly using the patient’s non-contrast CT scans. The software establishes size, location, and composition of kidney stones by analyzing 32 parameters. Clinicians can use the conclusive data to help determine effective treatment options, making it a crucial tool in kidney stone management.

David Smith, CEO of IQ-AI, said, “For the first time IQ-AI’s full range of products will have direct sales representation worldwide. We are very excited about the shared revenue potential of this agreement. Cortechs.ai has a well established and rapidly growing sales and marketing team who can introduce IB’s portfolio to their existing and new clients.”

IB’s products complement Cortechs.ai’ portfolio which specializes in assessing neurological conditions, including Alzheimer’s disease, multiple sclerosis, epilepsy, and traumatic brain injury.

“We are delighted to partner with IQ-AI to help bring their innovative products to market,” said Dr. Chris Airriess, CEO of Cortechs.ai. “Imaging Biometrics’ suite of products are very complementary to ours and help solve important clinical challenges faced by our global customer base.”

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. Please visit cortechs.ai for further information.

About IQ-AI, Ltd

IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.

More Resources

09/16/2025

OnQ Prostate for Focal Therapy

Read how OnQ Prostate supports focal therapy by personalizing prostate cancer care for patients while minimizing the risks associated with it.

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.
Scroll to Top